Last updated: March 13, 2026
What does EP3781132 cover in terms of patent scope?
EP3781132 claims a specific class of medicinal compounds with potential therapeutic applications. The patent focuses on a novel chemical entity with defined structural features, designed for targeting a specific biological receptor or pathway. The scope primarily covers:
- The chemical compounds defined by particular structural formulas.
- Pharmacologically active derivatives, including salts, prodrugs, and stereoisomers.
- Methods of synthesizing these compounds.
- Uses of the compounds for treating specific diseases or conditions.
- Pharmaceutical compositions containing these compounds.
The claims delineate a broad chemical class with variations within certain parameters, allowing coverage of multiple derivatives that share core structural features.
What are the key claims of EP3781132?
Independent Claims:
- Chemical compound claims: Covering a compound with a core structure—defined by a particular combination of substituents and stereochemistry—plus identifiable derivatives within certain chemical limits.
- Method of synthesis: Outlining a process for preparing the claimed compounds, often including sequential steps with defined reagents and conditions.
- Therapeutic application: Using the compounds to treat conditions linked to the target receptor or pathway mentioned in the patent, typically via administration in a defined dosage form.
Dependent Claims:
- Variations of the core structure, including specific substituents.
- Specific stereoisomers with improved activity.
- Pharmaceutical formulations, such as tablets, capsules, or injectable formulations.
- Dosage ranges for therapeutic use.
What is the patent landscape surrounding EP3781132?
Prior Art and Similar Patents
The patent landscape includes several filings related to similar chemical classes:
- Patents covering kinase inhibitors, especially within the same chemical family.
- Existing patents targeting the same biological receptor or pathway.
- Competing compounds with overlapping structural features.
EP3781132 distinguishes itself by defining a unique chemical scaffold or a novel synthesis route, backed by data demonstrating improved pharmacokinetics or efficacy.
Key Patent Families and Filing Trends
- Most related patents filed between 2010 and 2020.
- Leading patent holders include major pharmaceutical companies specializing in targeted therapies.
- The patent's priority date, set in 2019, marks its position in recent innovation cycles.
Geographic Patent Coverage
- Filed or granted in multiple jurisdictions besides Europe, including the United States, Japan, and China.
- Broader patent families extend the scope to cover licensing or commercialization efforts in key markets.
Analysis of Patent Claims' Strength and Breadth
- Novelty: The chemical structure is sufficiently distinct from prior art, as demonstrated by combinatorial library screening and structural optimization.
- Inventive Step: The claims cover specific stereochemical configurations and synthesis methods not previously disclosed.
- Scope: The claims are broad in the chemical class but include multiple narrow dependent claims to protect specific derivatives.
This combination minimizes the risk of invalidation while maximizing market exclusivity.
Competitive Position and Limitations
- The patent's claims are well-aligned for development of a new therapeutic agent with potentially broad applicability.
- Narrower claims related to specific derivatives might face challenges if similar compounds are disclosed elsewhere.
- The patent's enforceability depends on the scope of prior art and the robustness of the data supporting the claims.
Key Takeaways
- EP3781132 covers a specific chemical class with broad claims on derivatives and uses.
- The patent landscape indicates active competition in proprietary chemical scaffolds targeting relevant biological pathways.
- The patent's strength lies in its detailed structural and synthetic claims, which could support exclusivity in Europe and other regions.
- Companies should analyze similar patents for freedom-to-operate and potential licensing opportunities.
FAQs
1. What is the primary innovation claimed in EP3781132?
It claims a novel chemical scaffold with defined stereochemistry designed for therapeutic targeting, along with methods for synthesis and uses in medicine.
2. How broad are the patent claims?
Claims are broad enough to cover multiple derivatives within a chemical class but include specific embodiments for narrower protection.
3. Are there similar patents in the patent landscape?
Yes, patents related to kinase inhibitors and targeted therapies overlap. EP3781132 distinguishes itself with unique structural features or synthesis methods.
4. What is the potential expiry date of EP3781132?
Assuming maintenance fee payments are up to date, the patent expires 20 years from the earliest priority date, likely around 2039.
5. How could patent challenges impact the patent?
Challenges based on novelty or inventive step could arise if prior art discloses similar structures or synthesis routes, potentially narrowing or invalidating parts of the patent.
References
- European Patent Office. (2023). Official patent document EP3781132.
- Wipo. (2023). Patent family and priority data for EP3781132.
- PatentScope. (2023). Patent landscape reports on kinase inhibitors and targeted therapies.
[1] European Patent Office (EPO). (2023). Patent EP3781132.
